biopharma

Viral clearance studies are part of a multifaceted approach to ensure biopharmaceutical product safety. To prevent costly changes to a manufacturing process, it is important to assess each operation unit for its efficiency early on during downstream process development. See how a design of experiments (DOE) approach was utilized in this case study to investigate the effect of buffer pH and conductivity on the removal of impurities by an anion exchange (AEX) mixed-mode chromatography resin.

Large-scale downstream processing of viruses can face a range of obstacles different from those of many biotherapeutics. These challenges mostly arise from the size and complexity of the virus, which can affect product purity and recovery. Improvements of purification tools are necessary to overcome these challenges and must be engineered for easy scalability to meet manufacturing demands. In this video, Dr. Mark Snyder discusses common difficulties when developing purification strategies for vaccine production and gene therapy.

This webinar presents a downstream processing workflow for recombinant human insulin production from E. coli. Learn how proinsulin and insulin can be purified.

Immunotherapy has revolutionized cancer treatment, yet the drug discovery process to develop new biotherapeutic antibodies remains arduous. However, significant advances in antibody technology such as phage display have enabled fully human antibodies to be developed from animal-free libraries for just about any antigen.

In this webcast, see how Nuvia HP-Q Resin, an anion exchange resin, was used to purify oligonucleotides with phosphodiester backbones in a scaleable workflow.

Recombinant antibodies, CAR-T Cell Therapy Development, CAR-T Cell Therapy, Monoclonal Antibody Generation, custom antibodies, cell and gene therapy development, bioanalysis, biosimilar, immunogenicity, drug monitoring, antibody drug conjugate.

The CAR T-cell manufacturing process involves high potential for variability. Learn how sensitive ddPCR assays can be used to ensure safety and efficacy.

Whether you are part of a small academic lab or a multinational corporation, upgrading to a new quantitative PCR (qPCR) system can be both exciting and daunting. How will the new system perform compared to your current platform? Will your existing workflows translate smoothly? Read on to learn about our recent bridging study for users considering upgrading to the new CFX Opus Real-Time PCR System.

As more of the cell and gene therapies revolutionizing healthcare are approved for use, innovator companies usually get the credit. But many therapies would never make it to market without the expertise and capabilities of contract development and manufacturing organizations (CDMOs) operating behind the scenes. Learn more about how CDMOs enable new cell and gene therapies to come to market, and how Droplet Digital PCR can help.

Precision diagnostics for cancer. COVID-19 surveillance in wastewater. Quality control of cell and gene therapies. These were just a few of the cutting-edge applications on display at the Droplet Digital PCR (ddPCR) World 2021 symposium. Recapping the event in 5 takeaways, moderator Francisco Bizouarn shares how international experts are leveraging ddPCR technology to solve today’s scientific and public health problems.